XML 24 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
 
AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.
The following table summarizes the impact of the two-class method:
 
 
Three months ended
September 30,
 
Nine months ended
September 30,
(in millions, except per share data)
 
2020
 
2019
 
2020
 
2019
Basic EPS
 
 
 
 
 
 
 
 
Net earnings attributable to AbbVie Inc.
 
$
2,308

 
$
1,884

 
$
4,580

 
$
5,081

Earnings allocated to participating securities
 
17

 
10

 
44

 
27

Earnings available to common shareholders
 
$
2,291

 
$
1,874

 
$
4,536

 
$
5,054

Weighted-average basic shares outstanding
 
1,769

 
1,481

 
1,633

 
1,480

Basic earnings per share attributable to AbbVie Inc.
 
$
1.30

 
$
1.27

 
$
2.78

 
$
3.41

 
 
 
 
 
 
 
 
 
Diluted EPS
 
 
 
 
 
 
 
 
Net earnings attributable to AbbVie Inc.
 
$
2,308

 
$
1,884

 
$
4,580

 
$
5,081

Earnings allocated to participating securities
 
17

 
10

 
44

 
27

Earnings available to common shareholders
 
$
2,291

 
$
1,874

 
$
4,536

 
$
5,054

Weighted-average shares of common stock outstanding
 
1,769

 
1,481

 
1,633

 
1,480

Effect of dilutive securities
 
5

 
2

 
4

 
3

Weighted-average diluted shares outstanding
 
1,774

 
1,483

 
1,637

 
1,483

Diluted earnings per share attributable to AbbVie Inc.
 
$
1.29

 
$
1.26

 
$
2.77

 
$
3.41


Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.